Dr. Sahar Bedrood, MD, PhD

Dr. Bedrood practices at Specialty Surgical Center of Beverly Hills (Wilshire Blvd) in Beverly Hills, California.

Dr. Bedrood's NPI, 1871851923, was assigned on April 26, 2012. Dr. Bedrood graduated from Keck School of Medicine of USC in 2011. Dr. Bedrood holds California license A124192.

Dr. Bedrood's primary practice is Specialty Surgical Center of Beverly Hills (Wilshire Blvd), at 9001 Wilshire Blvd, Suite 100, Beverly Hills, CA 90211. The practice phone is (310) 275-2339.

Dr. Bedrood's primary practice is Specialty Surgical Center of Beverly Hills (Wilshire Blvd) in Beverly Hills, California. The medical group on file is PIH Health Physicians. Dmand AI also links Dr. Bedrood to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bedrood practices, 2 sites in all. Vendor and product names are available with a free account.

Retina specialist is Dr. Bedrood's primary specialty in the NPI Registry, under taxonomy code 207WX0107X. Dr. Bedrood is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Bedrood's licenses on file in 2 states: California and Maryland.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, conjunctivitis, dry eye, eye infection or inflammation, eyelid inflammation and glaucoma among the conditions Dr. Bedrood treats.

CMS data shows 3,724 Medicare services from Dr. Bedrood across 25 procedure codes in 2024, for 935 Medicare patients. Medicare paid $344,659 for them.

CMS counts 935 Medicare patients who saw Dr. Bedrood in 2024. The largest group is 65 to 74, with 378 patients. 75% of them have high cholesterol, and 67% have high blood pressure. 14% are also on Medicaid. Their average risk score is 1.14, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Bedrood's median patient age at 72, with 54% women.

In 2024, Dr. Bedrood wrote 2,330 Medicare Part D claims for 459 patients. 53% of them were for generic drugs. CMS names the drug for 2,213 of them, across 31 drugs with 11 or more claims each, at $365,241 in total drug cost. In 2023, CMS named 1,907 claims across 25 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Bedrood for performance year 2024, reported as part of a group. Dr. Bedrood accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 140 procedures of cataract surgery by Dr. Bedrood, more than 79% of the clinicians it reports for that procedure.

Dmand AI links 9 papers to Dr. Bedrood, published from 2010 to 2023. 2011 was the busiest year, with 2. The most frequent topics are Islet Amyloid Polypeptide, Microscopy, Electron and alpha-Synuclein. Dr. Bedrood's most frequent co-authors are Arsham Sheybani, MD, John Palmer Berdahl, MD and Peter Cawood Butler, MD.

CMS Open Payments shows 529 general payments to Dr. Bedrood from 30 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 60% of the total. Glaukos Corporation paid the most, $149,291.

Dr. Bedrood graduated from Keck School of Medicine of USC in 2011.

Dr. Bedrood is in network with 21 carriers, including Aetna, Blue Cross Blue Shield of Michigan and HCSC. HMO plans come from the most carriers, 13. Check the plan with the practice before a visit.